Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Fees To Spike In FY 2018, But Small Firms Get Breaks

Executive Summary

The standard US FDA fee for a 510(k) submission will increase 124% in FY 2018, but small companies will see a much more moderate 12% jump. Other fees will increase by between 30%-40% in the coming fiscal year. And, perhaps, the biggest change will be for de novo submissions, which will have a user fee for the first time. FDA issued its inflation-adjusted user-fee schedule following the recent enactment of MDUFA IV.

Advertisement

Related Content

Third-Party Review: FDA Seeks Tangible 510(k) Results Over Next Three Years
Most FDA User Fees Will Increase By Almost 4% Next Fiscal Year
'Refuse-To-Accept' Policy Outlined For De Novos In New US FDA Draft Guidance
MDUFA IV Makeover For US FDA Guidances
Device Week, Aug. 24, 2017: FDA Reauthorization Act Realities
US Device User-Fee Rates Will Drop About 10.3% In Fiscal 2017

Topics

Advertisement
UsernamePublicRestriction

Register

MT105377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel